These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33648343)

  • 1. ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: an example of evidence-based extrapolation.
    Muñoz Núñez F; Taxonera C; Marrón J
    Rev Esp Enferm Dig; 2021 Oct; 113(10):737-738. PubMed ID: 33648343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe.
    Jin R; Nduka C; Courmier D; Knight H; Meadows R; Piercy J; Cummings JRF; Radziszewski W
    Adv Ther; 2024 Jan; 41(1):331-348. PubMed ID: 37957522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
    Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
    Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo M; Fiorino G; Gilardi D; Furfaro F; Roda G; Loy L; Allocca M; Peyrin-Biroulet L; Danese S
    Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
    Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
    J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
    Ben-Horin S; Vande Casteele N; Schreiber S; Lakatos PL
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Biosimilars of Adalimumab.
    Kaushik VV
    J Assoc Physicians India; 2017 May; 65(5 Suppl):15-21. PubMed ID: 28836746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases.
    Somers M; Bossuyt P; Ferrante M; Peeters H; Baert F
    J Crohns Colitis; 2020 Jun; 14(5):680-685. PubMed ID: 31875891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study.
    Ribaldone DG; Caviglia GP; Pellicano R; Vernero M; Saracco GM; Morino M; Astegiano M
    Rev Esp Enferm Dig; 2020 Mar; 112(3):195-200. PubMed ID: 32054272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
    Macaluso FS; Cappello M; Busacca A; Fries W; Viola A; Costantino G; Magnano A; Vinci E; Ferracane C; Privitera AC; Piccillo G; Belluardo N; Giangreco E; Romano C; Citrano M; Graziano F; Garufi S; Bertolami C; Ventimiglia M; Scrivo B; Teresi G; Renna S; Rizzuto G; Casà A; Orlando A;
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3041-3049. PubMed ID: 34152636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases.
    Kay J; Cross RK; Feldman SR; Park Y; Hanauer SB
    Adv Ther; 2024 Feb; 41(2):509-533. PubMed ID: 38110655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
    Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
    McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
    Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SB5: An Adalimumab Biosimilar.
    Frampton JE
    BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.
    McConachie S; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):391-400. PubMed ID: 28095262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501).
    Francois F; Naimi L; Roblin X; Berger AE; Paul S
    BMC Immunol; 2021 Dec; 22(1):81. PubMed ID: 34953484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept.
    Ribaldone DG; Vernero M; Astegiano M
    Rev Esp Enferm Dig; 2021 Feb; 113(2):155. PubMed ID: 33207912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.